# Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma

> **NCT00482248** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 132 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT00482248
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2016-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482248, "Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00482248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*